Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases

Background KLS-1 is zinc (Zn) aspartate enriched with isotope (64)Zn to 99.2% mass fraction of total zinc. KLS-1 is intended as a novel therapeutic approach for patients with a variety of diseases including but not limited to different forms of cancer and neurodegenerative diseases. The purpose of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez, Jesus A, Lopez, Javier J, Torres Badillo, Claudia C, Gill, Jaya, Kesari, Santosh, Novak, Peter, Temnikov, Max, Byshovets, Roman, Bychkov, Oleg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637427/
https://www.ncbi.nlm.nih.gov/pubmed/36381721
http://dx.doi.org/10.7759/cureus.29921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637427/
https://www.ncbi.nlm.nih.gov/pubmed/36381721
http://dx.doi.org/10.7759/cureus.29921

Ejemplares similares